Heptaplatin

Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles[1].

Product Specifications

CAS Number

[146665-77-2]

Product Name Alternative

SKI 2053R

UNSPSC

12352300

Hazard Statement

H302-H315-H319-H335

Target

DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/heptaplatin.html

Solubility

10 mM in DMSO

Smiles

O=C(O[Pt]([NH2]C1)(O2)[NH2]C[C@@]3([H])OC(O[C@]13[H])C(C)C)CC2=O

Molecular Formula

C11H20N2O6Pt

Molecular Weight

471.36

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Kim NK, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer. 1999;86 (7) :1109-1115.